Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
